کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5969239 1576178 2014 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
One-year clinical outcomes of everolimus- versus sirolimus-eluting stents in patients with acute myocardial infarction
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
One-year clinical outcomes of everolimus- versus sirolimus-eluting stents in patients with acute myocardial infarction
چکیده انگلیسی


- We compared EES with PES in patients with AMI.
- EES and SES had similar rates of cardiac death, Re-MI, TLR, and stent thrombosis.
- The EES group had a lower rate of total MACE than the PES group did.
- EES has comparable or even better safety and efficacy compared to SES in AMI.

BackgroundIn contrast to many studies comparing everolimus-eluting stent (EES) with paclitaxel-eluting stent (PES), data directly comparing EES with sirolimus-eluting stent (SES) are limited, especially in patients with acute myocardial infarction (AMI).MethodsThis study includes 2911 AMI patients treated with SES (n = 1264) or EES (n = 1701) in Korea Acute Myocardial Infarction Registry (KAMIR). Propensity score matching was applied to adjust for baseline imbalance in clinical and angiographic characteristics, yielding a total of 2400 well-matched patients (1200 receiving SES and 1200 receiving EES). One-year clinical outcomes were compared between the two propensity score matched groups.ResultsBaseline clinical and angiographic characteristics were similar between the two propensity score matched groups. One-year clinical outcomes of the propensity score matched cohort were comparable between the EES versus the SES groups including the rates of cardiac death (4.8% vs. 4.8%, P = 1.000), recurrent myocardial infarction (1.4% vs. 1.7%, P = 0.619), target lesion revascularization (1.4% vs. 1.6%, P = 0.737), target lesion failure (7.0% vs. 7.3%, P = 0.752), and probable or definite stent thrombosis (0.5% vs. 0.9%, P = 0.224) except for a trend toward lower incidence of target vessel revascularization (1.9% vs. 3.0%, P = 0.087) and a lower rate of total major adverse cardiac events (9.3% vs. 11.9%, P = 0.034) in the EES group.ConclusionsThe present propensity score matched analysis performed in a large-scale, prospective, multicenter registry suggests that the second-generation drug-eluting stent EES has at least comparable or even better safety and efficacy profiles as compared with SES in the setting of AMI.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: International Journal of Cardiology - Volume 176, Issue 3, 20 October 2014, Pages 583-588
نویسندگان
, , , , , , , , , , , , , , , , ,